Chronic Hepatitis B Virus Market Insight, Epidemiology and Market Forecast -2030

‘Chronic Hepatitis B Virus (CHB) - Market Insights, Epidemiology and Market Forecast —2030’ report delivers an in-depth understanding of the CHB, historical and forecasted epidemiology as well as the CHB market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The CHB market report provides current treatment practices, emerging drugs, CHB market share of the individual therapies, current and forecasted CHB market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CHB treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
 

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017–2030
Chronic Hepatitis B Virus (CHB): Disease Understanding and Treatment Algorithm
 

Chronic Hepatitis B Virus Overview
Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.
HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1–2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).
The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in color, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterward.
 

Chronic Hepatitis B Virus Diagnosis
This condition is diagnosed with blood tests, which are also used to monitor its effects on the liver. For chronic cases, a liver biopsy may be needed. A biopsy is the removal of a sample of liver tissue for testing.
Screening for HBV involves a simple and relatively low-cost blood test to detect the presence of hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs) in serum. Patients who are HBsAg-negative and do not have antibodies are given the hepatitis B vaccine. Those who are HBsAg-negative and have detectable anti-HBs are already immune (generally from prior vaccination or recovery from an acute infection) and do not require further intervention or testing. A patient who tests positive for HBsAg has an active HBV infection, and further testing is needed to determine the phase of disease and course of action. Recommended initial follow-up testing includes serum ALT and HBV DNA levels, as well as serology for hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). Individuals with chronic HBV infection have circulating HBsAg persistently present in their serum for more than 6 months (without developing anti-HBs).
The hepatitis B virus specifically attacks the liver, so health care providers order blood tests to monitor the health of the liver. Some of the most common liver-related blood tests are described below.
These blood tests measure potential liver damage (or liver inflammation). If a person is infected with the hepatitis B virus, the liver cells can be injured by the virus, and then the liver enzymes can leak into the bloodstream. The higher the number, the greater the risk of potential liver damage.
 

Chronic Hepatitis B Virus Treatment
Currently, treatment strategies for CHB mainly include Antiviral medications. To this date, several drugs have been approved by the US FDA for the treatment of CHB: interferon-alpha and pegylated interferon-alpha, nucleoside analogs (NA) and nucleotide analog prodrugs. Oral antiviral medications include Tenofovir disoproxil (Viread), Tenofovir alafenamide (Vemlidy), Entecavir (Baraclude), Telbivudine (Tyzeka or Sebivo), Adefovir Dipivoxil (Hepsera), and Lamivudine (Epivir-HBV, Zeffix, or Heptodin). The aforementioned therapies help to fight the virus and slow its ability to damage the liver. Although NAs are well tolerated and exhibit an early and potent antiviral effect, however the selection of resistant mutants and nephrotoxicity during long-term therapy limit their use.
The therapies that are approved for the treatment of CHB are Tenofovir disoproxil (Viread), Tenofovir alafenamide (Vemlidy), Entecavir (Baraclude), Telbivudine (Tyzeka or Sebivo), Adefovir Dipivoxil (Hepsera), and Lamivudine (Epivir-HBV, Zeffix, or Heptodin), among others.
 

CHB Epidemiology
The CHB epidemiology division provides the insights about historical and current CHB patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
 

Key Findings
In the year 2017, the total prevalent cases of CHB was 5,797,240 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted CHB epidemiology segmented as [Total Prevalent Cases of CHB, Diagnosed cases of CHB, Gender-specific cases of CHB, Diagnosed cases of CHB by Age Distribution, Diagnosed cases of CHB by Impact on Liver, and Treated cases of CHB] scenario of CHB in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
 

Country Wise- CHB Epidemiology
Estimates show that the highest prevalent cases of CHB in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.
• The United States, in 2017, accounted for 2,276,030 CHB prevalent cases, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in EU5 were 2,231,406, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in Japan were 1,289,804, which are expected to grow during the study period, i.e., 2017–2030.
 

CHB Drug Chapters
Drug chapter segment of the CHB report encloses the detailed analysis of CHB marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the CHB clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
 

CHB Approved Drugs
Vemlidy/tenofovir alafenamide (Gilead Sciences)
Vemlidy is a novel, targeted prodrug of tenofovir manufactured by Gilead Sciences that has exhibited antiviral efficacy quite identical as Gilead’s Viread (tenofovir disoproxil fumarate, TDF) 300mg. Vemlidy was basically approved for the treatment of hepatitis B infection on the basis of a 48-week data from two international phase III studies (Studies 108 and 110). It was observed that Vemlidy was usually well-tolerated by patients in both studies and discontinuations due to adverse events were approximately 1% and 1.2%, respectively, apart from this the most commonly reported adverse events in both studies included headache, abdominal pain, fatigue, cough, nausea and back pain and occurred at similar rates in patients receiving Vemlidy.
Note: Detailed Current therapies assessment will be provided in the full report of CHB
 

CHB Emerging Drugs
JNJ-56136379/JNJ-6379 (Janssen Sciences)
JNJ-56136379 (JNJ-6379), is a Capsid Assembly Modulator (CAMs) being developed by Janssen Sciences. CAMs are basically being approached as new antiviral therapies having the potential to target capsid assembly that is defined as a very important step in the HBV life cycle, mediated by the core protein. JNJ-56136379 works via a dual mechanism of action, formerly by interfering with capsid assembly followed by preventing covalently closed circular DNA (cccDNA) formation at the time of de novo infection. It gets attached to HBV core protein and obstructing both early and late-stage processes in the HBV life cycle.
Sci-B-Vac (VBI Vaccines)
Sci-B-Vac is an advanced third-generation hepatitis B vaccine that has been licensed because of exhibiting safety and efficacy in millions of patients. It has been approved for its use and commercially-available in Israel. As claimed by the company it is “the only commercially-available tri-antigenic vaccine containing pre-S1, pre-S2, and S antigens of Hepatitis B”. Sci-B-Vac has not yet been approved for use by the US FDA or EMA. The recently completed global Phase III clinical program was designed to achieve the US FDA, EMA, and Health Canada market approvals for commercial sale of Sci-B-Vac in the United States, Europe, and Canada, respectively.
Vesatolimod/GS-9620 (Gilead Sciences)
Vesatolimod (GS-9620), is being developed in clinical studies for the treatment of Chronic Hepatitis B virus (HBV) infection by Gilead Sciences. GS-9620 induces a liver-targeting anti-viral effect inducing interferon-α (IFN-α) therapy. It demonstrates interferon-stimulated gene induction without detectable serum interferon at low oral doses. GS-9620 is a potent and oral agonist of Toll-Like Receptor-7 (TLR7), a pattern-recognition receptor whose activation results in innate and adaptive immune stimulation. Vesatolimod (GS-9620) was developed to induce a protective, virus-specific immune response to enhance HBsAg loss with Hepatitis B surface antibody (HBsAb) seroconversion.
GS-9688/Selgantolimod (Gilead Sciences)
 

Gilead Sciences’ selgantolimod (GS-9688) is an investigational oral selective small molecule agonist of toll-like receptor 8 (TLR8). Selgantolimod induces the cellular immune mediators, interleukin (IL)-12 and IL-8, as well as the antiviral cytokines tumor necrosis factor-α and interferon-γ (IFNγ) in vitro in human peripheral blood mononuclear cells. Selgantolimod also activates natural killer (NK) and mucosal associated invariant T cells, stimulates cluster of differentiation (CD)-8+ T-cell proliferation, and increase IFNγ production, while lowering programmed cell death protein 1 expression by HBV-specific CD8+-T cells in vitro in peripheral blood mononuclear cells. Selgantolimod-induced cytokines reduce HBV DNA, RNA, and antigen levels in HBV-infected primary human hepatocytes.
 

RG7854 and RG7907 combination (Roche)
RG7854 (previously known as RO7020531) and RG7907 (previously known as RO7049389) both are phase I investigational drugs under development by Roche for the indication hepatitis B virus (HBV). RG7854 is a TLR7 agonist, oral, small molecule immuno-modulator, activating the TLR (toll-like receptor) 7 and to a weaker extent TLR8. It has been developed as a best-in-disease for finite chronic hepatitis B combination therapy. Also, RG7907 (CpAM) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional core proteins, thereby effectively inhibiting HBV replication.
 

JNJ-73763989 and/or JNJ-56136379 (Janssen/Arrowhead Pharmaceuticals)
JNJ-3989, formerly ARO-HBV, is being developed in collaboration by Arrowhead Pharmaceuticals and Janssen Pharmaceuticals as a potentially curative therapy for patients with chronic hepatitis B infection when used in combination with other direct antivirals. JNJ-3989 is a ribonucleic acid interference (RNAi) therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this may allow the body’s natural immune defenses to clear the virus and potentially lead to a functional cure.
 

Cemiplimab/REGN2810 (Regeneron Pharmaceuticals)
Cemiplimab (REGN2810) is a human recombinant monoclonal IgG4 antibody to the programmed cell death receptor 1 (PD-1) which has distinctive immunomodulatory activity and is used in cancer immunotherapy. It is under investigation by Regeneron Pharmaceuticals for Hepatitis B Virus infection. Cemiplimab targets and blocks the PD-1 pathway, thus helping the immune system to fight cancer cells. It binds to the PD-1 receptor found on T-cells, blocking its interaction with PD ligand 1 (PD-L1) and PD-L2, thereby inhibiting T-cell proliferation and cytokine production. Cemiplimab was approved for use in cutaneous squamous cell carcinoma in the United States in 2018 and is currently under evaluation in several other forms of cancer, including non-small cell lung cancer, renal, ovarian and uterine carcinoma, lymphomas and multiple myeloma.
 

GSK3228836/ISIS 505358 or IONIS-HBVRX (GlaxoSmithKline/Ionis Pharma)
GSK3228836 (also known as ISIS 505358 or IONIS-HBVRX), is under the developmental process by the collaboration of GlaxoSmithKline (GSK) and Ionis Pharma. It is an antisense drug which is planned in order to lessen or inhibit the occurrence of the viral proteins linked with HBV infection and replication, including hepatitis B surface antigen (HBsAg), which is the main antigen involved in the defective prognosis of HBV infection, though its presence is marked in both acute as well as chronic infection but the level with they exist in the system is taken as the reference for differentiating between the two types of infection stated above.
 

GSK3389404/IONIS-HBV-LRX (GlaxoSmithKline/Ionis Pharma)
GSK3389404 (IONIS-HBV-LRX) is being developed by the collaboration of GlaxoSmithKline and Ionis Pharmaceuticals in order to develop a functional cure for CHB. It is basically defined as a liver-targeted antisense oligonucleotide or drug that suppresses functioning and synthesis of HBsAg along with other hepatitis B virus proteins that are the key players in the poor prognosis of the CHB infection.
 

ABI-H2158 (Assembly Biosciences)
ABI-H2158 is an investigational second-generation, potent and selective HBV core inhibitor, being developed by Assembly Bioscience. It has been observed and concluded that it has the ability to suppress viral replication by preventing the formation of cccDNA. The company has already completed its Phase I clinical trials (NCT04142762, and NCT04083716. In accordance with the positive outcomes, Assembly Biosciences has initiated a Phase II trial as well (NCT04398134; Recruiting), in order to evaluate the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72-week in combination with entecavir in participants with CHB virus infection. This trial is anticipated to be completed by January 2023.
 

Vebicorvir/VBR, or ABI-H0731 (Assembly Biosciences)
ABI-H0371 is a lead investigational candidate from Assembly Biosciences. It is an antiviral therapy that is directed towards the viral suppression of HBV antigens. The company has already completed a Phase Ia study where it was assessed for its pharmacokinetics, safety, and tolerability study in healthy volunteers. It had shown potential antiviral effects and the data was presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting) in November 2018.
Note: Detailed emerging therapies assessment will be provided in the final report.
 

CHB Market Outlook
Currently, treatment strategies for CHB mainly include Antiviral medications. To this date, several drugs have been approved by the US FDA for the treatment of CHB: interferon-alpha and pegylated interferon-alpha, nucleoside analogs (NA) and nucleotide analog prodrugs. Oral antiviral medications include Tenofovir disoproxil (Viread), Tenofovir alafenamide (Vemlidy), Entecavir (Baraclude), Telbivudine (Tyzeka or Sebivo), Adefovir Dipivoxil (Hepsera), and Lamivudine (Epivir-HBV, Zeffix, or Heptodin). The aforementioned therapies help to fight the virus and slow its ability to damage the liver. Although NAs are well tolerated and exhibit an early and potent antiviral effect, however the selection of resistant mutants and nephrotoxicity during long-term therapy limit their use. It is important to mention that INF-α was the first substance licensed to treat CHB virus infections. At present, two types of interferon have been approved for CHB treatment: interferon α-2b (Intron A; Schering-Plough) and pegylated interferon α-2a (PEG-IFN; Pegasys; Roche). Lamivudine was approved in 1998 by the US FDA for the treatment of chronic hepatitis B infections. It was the first NAs to be approved for the treatment of CHB. In 1998, the approval for the drug was granted for adults and in 2001 for children aged 2–17 years. However, this drug has been used and approved for HIV infection since 1995.
In addition to this, Adefovir is the second NA approved for the treatment of CHB and has been shown to be effective in both HBeAg-positive and HBeAg-negative CHB. Adefovir dipivoxil was licensed in the United States as Hepsera in 2002 for the treatment of CHB. Hepsera 10 mg is indicated for the treatment of chronic hepatitis B infection in patients 12 years of age and older. It is administered orally at a dose of 10 mg daily. This candidate was also initially developed as an antiretroviral drug for HIV infection, however, was abandoned due to the high rate of nephrotoxicity at high doses. This candidate is approved in Europe in 2003, and GlaxoSmithKline commercializes the product in Japan, China, and Saudi Arabia.
 

“It is worth mentioning that, currently, the preferred first-line oral antiviral therapies for CHB as recommended by the American Association for the Study of Liver Diseases (AASLD) include tenofovir disoproxil fumarate, entecavir, and more recently, tenofovir alafenamide. In addition to the AASLD, as per the guidelines from the European Association for the Study of the Liver (EASL), the preferred regimens are entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide as monotherapies as one of the preferred first-line therapies to treat CHB.”
In conclusion, it can be summarized that as many potential therapies are being investigated for the management of CHB, it is safe to predict that the treatment space will experience a significant impact during the forecast period of 2020–2030.
Note: Detailed Market Outlook will be provided in the final report.
 

Key Findings
The CHB market size in the 7MM is expected to change during the study period 2017–2030. The therapeutic market of CHB in the seven major markets was USD 1,657 million in 2017 which is expected to increase during study period (2017–2030). According to the estimates, the highest market size of CHB is found in the United States followed by Japan and Germany.
 

The United States Market Outlook
In 2017, the total market size of CHB therapies was USD 1,097 million in the United States which is expected to increase in the study period (2017–2030).
EU-5 Countries: Market Outlook
In 2017, the total market size of CHB therapies was USD 312 million in the EU-5 countries which is expected to increase in the study period (2017–2030).
 

Japan Market Outlook
The total market size of CHB therapies in Japan was USD 249 million in 2017 which is expected to increase in the study period (2017–2030).
CHB Pipeline Development Activities
 

The drugs which are in pipeline include:
1. JNJ-56136379/JNJ-6379 (Janssen Sciences)
2. Sci-B-Vac (VBI Vaccines)
3. Vesatolimod/GS-9620 (Gilead Sciences)
4. GS-9688/Selgantolimod (Gilead Sciences)
5. RG7854 and RG7907 combination (Roche)
6. JNJ-73763989 and/or JNJ-56136379 (Janssen/Arrowhead Pharmaceuticals)
7. Cemiplimab/REGN2810 (Regeneron Pharmaceuticals)
8. GSK3228836/ISIS 505358 or IONIS-HBVRX (GlaxoSmithKline/Ionis Pharma)
9. GSK3389404/IONIS-HBV-LRX (GlaxoSmithKline/Ionis Pharma)
10. ABI-H2158 (Assembly Biosciences)
11. Vebicorvir/VBR, or ABI-H0731 (Assembly Biosciences)
Note: Detailed emerging therapies assessment will be provided in the final report.
 

CHB Drugs Uptake
Tenofovir alafenamide (TAF) is slowly making its way in to the CHB market but the uptake is not so fast especially in European countries. Advantage of TAF over TDF is that the TDF could treat the hep B virus at less than one-tenth the dose of its predecessor, tenofovir disoproxil fumarate (TDF). Because of that, TAF is much less damaging to patients bone density and kidney health. Clinical data from TAF indicated that it has similar efficacy to TDF. Among emerging therapies, JNJ-3989 ± JNJ-6379 + NUC combo expected to provide better functional cure compared to current therapies and expected to impact the CHB market
 

Access and Reimbursement Scenario in CHB Therapies
There are about seven medications approved for the management and treatment of CHB, five of them belong to the Antivirals or NRTIs class of drugs in which they are further segmented as First and Second Line of Treatment, while the second class of medication prescribed is Interferons, this group consists of Conventional Interferons and Pegylated interferons. Several factors have been identified to influence medication adherence, including age, education, marital status, social medical support; disease severity; therapy effectiveness; and cost and affordability which can be strongly influenced by market access and reimbursement scheme.
Vaccination programs are also available in order to promote the eradication of HBV infection even before its onset and transmission.
• In February 2006, Adefovir dipivoxil and peginterferon alfa-2a recommended by NICE as an option for the initial treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative), within its licensed indications.
• In August 2008, Entecavir, recommended by NICE as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.
• In January 2019, Tenofovir alafenamide was recommended by IQWiG for added benefit not proven for any of the 4 sub indications.
Note: Detailed Access and Reimbursement Scenario will be provided in the final report.
 

KOL-Views
To keep up with current market trends, we take KOLs and SME’s opinion working in CHB domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or CHB market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
 

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the CHB Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
 

Scope of the Report
• The report covers the descriptive overview of CHB, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the CHB epidemiology and treatment in the 7MM.
• Additionally, an CHB-inclusive account of both the current and emerging therapies for CHB is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of CHB market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CHB market.
 

Report Highlights
• In the coming years, CHB market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence CHB R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for CHB. Launch of emerging therapies, will significantly impact the CHB market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CHB.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
 

CHB Report Insights
• Patient Population
• Therapeutic Approaches
• CHB Pipeline Analysis
• CHB Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
 

CHB Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• CHB Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
 

CHB Report Assessment
• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers
 

Key Questions
 

Market Insights:
• What was the CHB Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the CHB total market size as well as market size by therapies across the 7MM during the study period (2017–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest CHB market size during the study period (2017–2030)?
• At what CAGR, the CHB market is expected to grow in the 7MM during the study period (2017–2030)?
• What would be the CHB market outlook across the 7MM during the study period (2017–2030)?
• What would be the CHB market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• CHB patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the CHB market?
 

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of the CHB?
• What is the historical CHB patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of CHB in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
• Out of all the 7MM countries, which country would have the highest prevalent population of CHB during the study period (2017–2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CHB?
 

Current Treatment Scenario and Emerging Therapies:
• What are the current options for the treatment of CHB?
• What are the current treatment guidelines for the treatment of CHB in the US, Europe and Japan?
• How many companies are developing therapies for the treatment of CHB?
• How many therapies are developed by each company for the treatment of CHB?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of CHB?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CHB therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CHB and their status?
• What are the key designations that have been granted for the emerging therapies for CHB?
• What is the global historical and forecasted market of CHB?
 

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the CHB market.
• To understand the future market competition in the CHB market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for CHB in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for CHB market.
• To understand the future market competition in the CHB market.

List Of Tables

Table 1: Summary of CHB Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total Prevalent Cases of CHB in the 7MM (2017–2030)
Table 3: Total Diagnosed Prevalent cases of CHB in the 7MM (2017–2030)
Table 4: Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM (2017–2030)
Table 5: Age-specific Prevalent Cases of CHB in the 7MM (2017–2030)
Table 6: Diagnosed Prevalent Cases of CHB by Impact on Liver in the 7MM (2017–2030)
Table 7: Total Treated cases of CHB in the 7MM (2017–2030)
Table 8: Total Prevalent Cases of CHB in the United States (2017–2030)
Table 9: Total Diagnosed Prevalent cases of CHB in the United States (2017–2030)
Table 10: Gender-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)
Table 11: Age-specific Prevalent Cases of CHB in the United States (2017–2030)
Table 12: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United States (2017–2030)
Table 13:Total Treated cases of CHB in the United States (2017–2030)
Table 14: Total Prevalent Cases of CHB in Germany (2017–2030)
Table 15: Total Diagnosed Prevalent cases of CHB in Germany (2017–2030)
Table 16: Gender-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)
Table 17: Age-specific Prevalent Cases of CHB in Germany (2017–2030)
Table 18: Diagnosed Prevalent Cases of CHB by Impact on Liver in Germany (2017–2030)
Table 19: Total Treated cases of CHB in Germany (2017–2030)
Table 20: Total Prevalent Cases of CHB in France (2017–2030)
Table 21: Total Diagnosed Prevalent cases of CHB in France (2017–2030)
Table 22: Gender-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)
Table 23: Age-specific Prevalent Cases of CHB in France (2017–2030)
Table 24: Diagnosed Prevalent Cases of CHB by Impact on Liver in France (2017–2030)
Table 25: Total Treated cases of CHB in France (2017–2030)
Table 26: Total Prevalent Cases of CHB in Italy (2017–2030)
Table 27: Total Diagnosed Prevalent cases of CHB in Italy (2017–2030)
Table 28: Gender-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)
Table 29: Age-specific Prevalent Cases of CHB in Italy (2017–2030)
Table 30: Diagnosed Prevalent Cases of CHB by Impact on Liver in Italy (2017–2030)
Table 31: Total Treated cases of CHB in Italy (2017–2030)
Table 32:Total Prevalent Cases of CHB in Spain (2017–2030)
Table 33: Total Diagnosed Prevalent cases of CHB in Spain (2017–2030)
Table 34: Gender-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)
Table 35: Age-specific Prevalent Cases of CHB in Spain (2017–2030)
Table 36: Diagnosed Prevalent Cases of CHB by Impact on Liver in Spain (2017–2030)
Table 37: Total Treated cases of CHB in Spain (2017–2030)
Table 38:Total Prevalent Cases of CHB in the United Kingdom (2017–2030)
Table 39: Total Diagnosed Prevalent cases of CHB in the United Kingdom (2017–2030)
Table 40: Gender-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)
Table 41: Age-specific Prevalent Cases of CHB in the United Kingdom (2017–2030)
Table 42: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United Kingdom (2017–2030)
Table 43: Total Treated cases of CHB in the United Kingdom (2017–2030)
Table 44: Total Prevalent Cases of CHB in Japan (2017–2030)
Table 45: Total Diagnosed Prevalent cases of CHB in Japan (2017–2030)
Table 46: Gender-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)
Table 47: Age-specific Prevalent Cases of CHB in Japan (2017–2030)
Table 48: Diagnosed Prevalent Cases of CHB by Impact on Liver in Japan (2017–2030)
Table 49: Total Treated cases of CHB in Japan (2017–2030)
Table 50: Anti-hepatitis B virus (HBV) cytokine and nucleot(s)ide analog therapeutic agents
Table 51: Recommendation of EASL
Table 52: Preferred Antiviral Treatment of the HBsAg (+) Patient
Table 53: For Chronic Hepatitis B
Table 54: Trials Conducted with Vemlidy in Adults with Chronic HBV Infection
Table 55: Tenofovir Alafenamide (TAF), Clinical Trial Description, 2020
Table 56: GSK3228836 (IONIS-HBVRx); Clinical Trial Description, 2020
Table 57: GSK3389404 (IONIS-HBV-LRX);Clinical Trial Description, 2020
Table 58: ABI-H2158; Clinical Trial Description, 2020
Table 59: ABI-H0371; Clinical Trial Description, 2020
Table 60: JNJ-56136379 (JNJ-6379); Clinical Trial Description, 2020
Table 61: Sci-B-Vac; Clinical Trial Description, 2020
Table 62: Vesatolimod (GS-9620), Clinical Trial Description, 2020
Table 63: GS-9688, Clinical Trial Description, 2020
Table 64: RG7854 and RG7907, Clinical Trial Description, 2020
Table 65: JNJ-3989, Clinical Trial Description, 2020
Table 66: Cemiplimab, Clinical Trial Description, 2020
Table 67: 7MM Market Size of CHB, in USD Million (2017–2030)
Table 68: 7MM Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 69: United States Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 70: Germany Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 71: France Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 72: Italy Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 73: Spain Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 74: United Kingdom Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 75: Japan Market Size of CHB by Therapies, in USD Million (2017–2030)
Table 76: NHS Recommendation about Vaccination programs
Table 77: NHS Recommendation about Peginterferon alfa 2-a and Antiviral medicine
Table 78: NICE Recommendations
Table 79: Medicines not reimbursed through national prices and directly commissioned by NHS England
Table 80: IQWiG Recommendation for the treatment of CHB
Table 81: HAS Recommendation for treatment of CHB
Table 82: Reimbursement policy of Medicare
Table 83: Japan Reimbursement policy

List Of Figures

Figure 1: Chronic Hepatitis B SWOT Analysis
Figure 2: Epidemiology and Market Methodology
Figure 3: Progression of Hepatitis B infection
Figure 4: Acute Hepatitis B Infection
Figure 5: Chronic Hepatitis B Infection
Figure 6: Chronic Hepatitis B Infection by age
Figure 7: Signs and Symptoms of Hepatitis B Infection
Figure 8: Signs and Symptoms of Acute and Chronic Hepatitis B Infection
Figure 9: Risk factors of Hepatitis B Infection
Figure 10: Transmission of Hepatitis B Virus
Figure 11: Steps in HBV replication
Figure 12: Pathophysiology of Hepatitis B Infection
Figure 13: Serologic course of hepatitis B virus (HBV) infection.
Figure 14: Phases of Chronic Hepatitis B Infection
Figure 15: Complications of Hepatitis B Infection
Figure 16: HBV Screening Algorithm for at-risk patients
Figure 17: Interpretation of Results
Figure 18: Hepatitis B Infection Profile
Figure 19: Transient Elastography using FibroScan
Figure 20: Total Prevalent Cases of CHB in the 7MM (2017–2030)
Figure 21: Total Diagnosed Prevalent cases of CHB in the 7MM (2017–2030)
Figure 22: Gender-specific Diagnosed Prevalent Cases of CHB in the 7MM (2017–2030)
Figure 23: Age-specific Diagnosed Prevalent Cases of CHB in the 7MM (2017–2030)
Figure 24: Diagnosed Prevalent Cases of CHB by Impact on Liver in the 7MM (2017–2030)
Figure 25: Treated cases of CHB in the 7MM (2017–2030)
Figure 26: Total Prevalent Cases of CHB in the United States (2017–2030)
Figure 27: Total Diagnosed Prevalent cases of CHB in the United States (2017–2030)
Figure 28: Gender-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)
Figure 29: Age-specific Diagnosed Prevalent Cases of CHB in the United States (2017–2030)
Figure 30: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United States (2017–2030)
Figure 31: Treated cases of CHB in the United States (2017–2030)
Figure 32: Total Prevalent Cases of CHB in Germany (2017–2030)
Figure 33: Total Diagnosed Prevalent cases of CHB in Germany (2017–2030)
Figure 34: Gender-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)
Figure 35:Age-specific Diagnosed Prevalent Cases of CHB in Germany (2017–2030)
Figure 36: Diagnosed Prevalent Cases of CHB by Impact on Liver in Germany (2017–2030)
Figure 37: Treated cases of CHB in Germany (2017–2030)
Figure 38: Total Prevalent Cases of CHB in France (2017–2030)
Figure 39: Total Diagnosed Prevalent cases of CHB in France (2017–2030)
Figure 40: Gender-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)
Figure 41:Age-specific Diagnosed Prevalent Cases of CHB in France (2017–2030)
Figure 42: Diagnosed Prevalent Cases of CHB by Impact on Liver in France (2017–2030)
Figure 43: Treated cases of CHB in France (2017–2030)
Figure 44: Total Prevalent Cases of CHB in Italy (2017–2030)
Figure 45: Total Diagnosed Prevalent cases of CHB in Italy (2017–2030)
Figure 46: Gender-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)
Figure 47: Age-specific Diagnosed Prevalent Cases of CHB in Italy (2017–2030)
Figure 48: Diagnosed Prevalent Cases of CHB by Impact on Liver in Italy (2017–2030)
Figure 49: Treated cases of CHB in Italy (2017–2030)
Figure 50: Total Prevalent Cases of CHB in Spain (2017–2030)
Figure 51: Total Diagnosed Prevalent cases of CHB in Spain (2017–2030)
Figure 52: Gender-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)
Figure 53: Age-specific Diagnosed Prevalent Cases of CHB in Spain (2017–2030)
Figure 54: Diagnosed Prevalent Cases of CHB by Impact on Liver in Spain (2017–2030)
Figure 55: Treated cases of CHB in Spain (2017–2030)
Figure 56: Total Prevalent Cases of CHB in the United Kingdom (2017–2030)
Figure 57: Total Diagnosed Prevalent cases of CHB in the United Kingdom (2017–2030)
Figure 58: Gender-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)
Figure 59: Age-specific Diagnosed Prevalent Cases of CHB in the United Kingdom (2017–2030)
Figure 60: Diagnosed Prevalent Cases of CHB by Impact on Liver in the United Kingdom (2017–2030)
Figure 61: Treated cases of CHB in the United Kingdom (2017–2030)
Figure 62: Total Prevalent Cases of CHB in Japan (2017–2030)
Figure 63: Total Diagnosed Prevalent cases of CHB in Japan (2017–2030)
Figure 64: Gender-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)
Figure 65: Age-specific Diagnosed Prevalent Cases of CHB in Japan (2017–2030)
Figure 66: Diagnosed Prevalent Cases of CHB by Impact on Liver in Japan (2017–2030)
Figure 67: Treated cases of CHB in Japan (2017–2030)
Figure 68: Classes of drugs for the treatment of HBV infection
Figure 69: Types of Interferons
Figure 70: Types of NRTIs
Figure 71: Treatment Pattern
Figure 72: Treatment Pattern
Figure 73: Week 12 and 24, stopping rules for HBeAg-positive and -negative patients treated with PegIFNa. These rules are based upon viral genotype, HBsAg, and HBV levels.
Figure 74: Treatment algorithm in the case of HBsAg positive and HBeAg negative
Figure 75: Treatment algorithm in the case of HBsAg (+) and HBeAg (+)
Figure 76: Treatment algorithm in the case of HBeAg Negative
Figure 77: Unmet Needs for Chronic Hepatitis B Virus
Figure 78: Hepatitis D: coinfection and superinfection with Hepatitis B
Figure 79: Mechanism of action
Figure 80: Difference between Third and Second generation Hepatitis B Vaccine
Figure 81: Mechanism of Action of Vesatolimod
Figure 82: Mechanism of Action of RG7854 and RG7907 combination
Figure 83: Mechanism of action of RNAi Therapeutic
Figure 84: Market Size of CHB in the 7MM, in USD Billion (2017–2030)
Figure 85: Market Size of CHB in the 7MM by Therapies, in USD Billion (2017–2030)
Figure 86: Market Size of CHB in the United States by Therapy, in USD Billion (2017–2030)
Figure 87: Market Size of CHB in Germany by Therapies, in USD Billion (2017–2030)
Figure 88: Market Size of CHB in France by therapies, in USD Billion (2017–2030)
Figure 89: Market Size of CHB in Italy by Therapies, in USD Billion (2017–2030)
Figure 90: Market Size of CHB in Spain by therapies, in USD Billion (2017–2030)
Figure 91: Market Size of CHB in the United Kingdom by Therapies, in USD Billion (2017–2030)
Figure 92: Market Size of CHB in Japan by Therapy, in USD Billion (2017–2030)
Figure 93: Market Drivers
Figure 94: Market Barriers

Fill The Form For Sample Request

There is no Reviews available